Literature DB >> 1898753

Cost-effectiveness of strategies for detecting diabetic retinopathy.

E J Dasbach1, D G Fryback, P A Newcomb, R Klein, B E Klein.   

Abstract

A computer model has been developed to determine cost-effectiveness of screening and treatment for diabetic retinopathy from a societal viewpoint. This model was used to evaluate biannual and annual screening programs using ophthalmoscopy, fundus photography with a "nonmydriatic camera," and photography with a "mydriatic camera." Computations were performed for three subpopulations formed by patients with younger onset diabetes (age at diagnosis less than 30 years) of 5 years or more duration, with older onset diabetes (age at diagnosis greater than or equal to 30 years) who are taking insulin, and with older onset diabetes not taking insulin. Population characteristics are from a well-described southern Wisconsin population where data are available, but the computer model may be specialized to other population. Generally costs of screening programs appear to be recovered by avoided costs of blindness in the population subgroups taking insulin; however, the cost of screening programs generally are not recovered by avoiding costs of blindness in the older onset population subgroup not taking insulin. It was estimated that supplying annual examination with mydriatic fundus photography as a screening program to a cohort of 1,000 diabetics from the younger onset population who have been diagnosed at least 5 years and who are currently not receiving care might save 319 sight years over the lifetime of the cohort. This program will save 62 sight years in an older onset cohort who are taking insulin, and 21 sight years in the older onset population not taking insulin (all benefits are presented as present values computed with an annual discount rate of 5%). Other programs achieve slightly lower savings in each subpopulation.

Entities:  

Mesh:

Year:  1991        PMID: 1898753     DOI: 10.1097/00005650-199101000-00003

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  29 in total

1.  Costs of diabetes. A methodological analysis of the literature.

Authors:  E Pagano; M Brunetti; F Tediosi; L Garattini
Journal:  Pharmacoeconomics       Date:  1999-06       Impact factor: 4.981

2.  Complications of diabetes: screening for retinopathy and management of foot ulcers.

Authors:  A Melville; R Richardson; A McIntosh; C O'Keeffe; J Mason; J Peters; A Hutchinson
Journal:  Qual Health Care       Date:  2000-06

Review 3.  What is the cost of blindness?

Authors:  C Meads; C Hyde
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 4.  The cost-effectiveness of three screening alternatives for people with diabetes with no or early diabetic retinopathy.

Authors:  David B Rein; John S Wittenborn; Xinzhi Zhang; Benjamin A Allaire; Michael S Song; Ronald Klein; Jinan B Saaddine
Journal:  Health Serv Res       Date:  2011-04-14       Impact factor: 3.402

5.  Modeling transition rates using panel current-status data: how serious is the bias?

Authors:  Douglas A Wolf; Thomas M Gill
Journal:  Demography       Date:  2009-05

6.  Frequency of Evidence-Based Screening for Retinopathy in Type 1 Diabetes.

Authors:  David M Nathan; Ionut Bebu; Dean Hainsworth; Ronald Klein; William Tamborlane; Gayle Lorenzi; Rose Gubitosi-Klug; John M Lachin
Journal:  N Engl J Med       Date:  2017-04-20       Impact factor: 91.245

7.  Optimal screening schedules for disease progression with application to diabetic retinopathy.

Authors:  Ionut Bebu; John M Lachin
Journal:  Biostatistics       Date:  2018-01-01       Impact factor: 5.899

8.  Diabetic retinopathy.

Authors:  Fadia T Shaya; Mohammad Aljawadi
Journal:  Clin Ophthalmol       Date:  2007-09

9.  Teleretinal imaging to screen for diabetic retinopathy in the Veterans Health Administration.

Authors:  Anthony A Cavallerano; Paul R Conlin
Journal:  J Diabetes Sci Technol       Date:  2008-01

10.  A diabetes control program in a public health care setting.

Authors:  S B Baker; C Vallbona; V Pavlik; C E Fasser; M Armbruster; R McCray; R L Baker
Journal:  Public Health Rep       Date:  1993 Sep-Oct       Impact factor: 2.792

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.